Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Non-Adjuvanted MCV-5
- Development stage
- Phase 3
- Lead developer
- Serum Institute of India
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Non-Adjuvanted MCV-5 is a candidate polyvalent conjugate vaccine developed to prevent meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, W, and X. Unlike currently licensed quadrivalent vaccines (which cover A, C, Y, W), this vaccine also targets serogroup X—a strain responsible for outbreaks in Africa and Europe for which no previous vaccine existed. The formulation consists of capsular polysaccharides from the five targeted serogroups conjugated to protein carriers (CRM197 and tetanus toxoid). The non-adjuvanted version does not include aluminum phosphate or other adjuvant substances. It is intended primarily for use in regions where all five serogroups are endemic or epidemic threats[4]. Clinical studies have focused on evaluating both safety and immunogenicity of adjuvanted versus non-adjuvanted formulations[2][4].
- Brand names
- MenFive
- Other names
- Non-Adjuvanted MCV-5nonadjuvanted MCV-5NmCV-5NmCV5NmCV 5
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)MenX CPS (Neisseria meningitidis serogroup X capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)
Beyond the preview
Go deeper on Non-Adjuvanted MCV-5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Non-Adjuvanted MCV-5.